HFA Premium Access

SGLT2 inhibitors: what is the evidence so far?

Topic: Diabetes and the Heart
Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance

Congress Presentation

About the speaker

Professor Javed Butler

Baylor Scott and White Health, Dallas (United States of America)
105 presentations
14 followers

4 more presentations in this session

Welcome and introduction - Know it by heart – New opportunities for cardiologists in the SGLT2 inhibitor era.

Speaker: Professor F. Ruschitzka (Zurich, CH)

Thumbnail

Advancing evidence-based care in patients with type 2 diabetes: new opportunities for cardiologists.

Speaker: Professor R. Fontes Carvalho (Vila Nova de Gaia, PT)

Thumbnail

Ongoing studies with SGLT2 inhibitors: how may new and emerging evidence inform future clinical practice?

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Thumbnail

Summary and close - Know it by heart – New opportunities for cardiologists in the SGLT2 inhibitor era.

Speaker: Professor F. Ruschitzka (Zurich, CH) Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Thumbnail

Access the full session

Know it by heart – New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era

Speakers: Professor J. Butler, Professor F. Ruschitzka, Professor R. Fontes Carvalho, Professor F. Zannad, Professor F. Ruschitzka...
Thumbnail

About the event

Image

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb